ERBB2 and breast cancer: Similarly, melittin was significantly more potent against HER2-enriched breast cancer and TNBC compared to normal cells (Fig. 1b, c, right; Table 1; GLM, Wald Chi-Square = 12.9, p < 0.001, n = 33, df = 1), with IC50 values from 0.94 to 1.49 μM in human TNBC and HER2-enriched breast cancer cells, and 1.03 to 2.62 μM in nontransformed cells.